James has a distinguished career in health care spanning more than thirty years. His accomplishments are well recognized as an investor, operating executive, and entrepreneur. During the last fourteen years, he held numerous executive positions at Abbott including Corporate Vice President Pharmaceutical and Nutritional Products Group Business Development, Senior Vice President Global Nutrition, and Executive Vice President Global Pharmaceuticals. He retired as President, Abbott Biotech Ventures. In his last three positions prior to retiring from Abbott, James reported to the Chairman and Chief Executive Officer.
From 2000 to 2010, James was a significant contributor to Abbott's most defining endeavors. Within the pharmaceutical operating division, James was integrally involved in every major transaction executed by the company including the acquisitions of BASF Pharmaceuticals, KOS Pharmaceuticals, Solvay Pharmaceuticals and Piramal Health Solutions. He was also responsible for the restructuring of TAP, Abbott's highly successful joint venture with Takeda Chemicals of Japan. In addition, James identified and analyzed more than one thousand pharmaceutical in-licensing and out-licensing opportunities for Abbott, and drove a substantial number of them to successful transactions. James was also directly responsible for establishing and managing Abbott Global Nutrition, Abbott's second largest and profitable operating division.
Prior to joining Abbott, James was the President of Sugen, Inc., a biotechnology company focused in oncology. James led the company's initial public offering in 1994 and subsequently shaped the company to make it an attractive acquisition target. The company was acquired by Pharmacia in 1997. Earlier in his career, James held management positions in Bristol-Myers Squibb, Pfizer, and Abbott. Over his entire career, he is a four time expatriate living and working six and a half years in Latin America and seven years in Japan.
James is a member of the Advisory Board of the University Of Chicago Graduate School Of Business (Booth). He is a Special Advisor to the Chancellor of UC Davis Sacramento. James serves as an independent director of Depomed, SonarMed, Genelux, ChemoCentryx and Theravance.
James earned his MBA from the Kelley School of Business at Indiana University, as well as two bachelor degrees in psychology and forensic studies from Indiana University.
Enzo brings almost two decades of leading private equity investment and corporate finance experience. He previously worked at Norwest Equity Partners which managed $5 billion of investment capital from Minnesota, Wind Point Partners which managed $2 billion of investment capital from Illinois and Michigan, and American Securities which managed $2 billion of investment capital from New York. Prior to entering the private equity industry, Enzo focused on corporate finance merger & acquisition advisory and lending for private equity investments while at Credit Suisse investment banking in New York.
Enzo holds an MBA with honors from the Kellogg School of Management at Northwestern University, is a Chartered Financial Analyst, and received an undergraduate business degree with honors from the Richard Ivey School of Business at the University of Western Ontario.
Michael has over one and a half decades of leading private equity investment and corporate finance experience. He previously worked at Flexpoint Ford which managed $1 billion of investment capital from Illinois and New York and was one of the initial investment professionals hired. Michael also worked at Stark Investments in Wisconsin, at the time a $15 billion hedge fund investing in equity securities. Prior to entering private equity, Michael worked in corporate finance and merger & acquisition advisory for different sized healthcare companies while at Lazard investment banking in New York.
Michael holds an MBA from the Kellogg School of Management at Northwestern University and an undergraduate double major in economics and biological sciences with Phi Beta Kappa and Student Marshal distinction from the University of Chicago.
Ryan brings almost a decade of private equity and investment banking experience. He previously worked at Prism Capital which managed almost $200 million of investment capital from Chicago. Prior to entering the private equity industry, Ryan focused on corporate finance merger & acquisition advisory while at Houlihan Capital in Chicago.
Ryan holds an MBA from the Kellogg School of Management at Northwestern University, and received an undergraduate finance degree from Augustana College.
Nathan brings almost a decade of private equity and investment banking experience. He previously worked at CHS (Code Hennessy & Simmons) Capital which managed $2.3 billion of investment capital from Chicago. Nathan also worked in corporate finance and merger & acquisition advisory at Goldman, Sachs & Co. in New York and Lincoln International in Chicago.
Nathan holds an MBA from the Kellogg School of Management at Northwestern University and received an undergraduate business degree with distinction from the Kelley School of Business at Indiana University.